Sugi Predict

Sugi Predict / Compounds / SCHEMBL435369

SCHEMBL435369

SCHEMBL435369

COc1cc(OC)c2c(=O)[nH]c(-c3ccc(N4CCN(C(=O)c5ccncc5)CC4)cc3)nc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 7/20 0.57
▸ ALDH1A1 P00352 2/20 0.56
▸ GAA P10253 1/20 0.56
▸ HDAC3 O15379 9/20 0.51
▸ HDAC4 P56524 9/20 0.51
▸ HDAC1 Q13547 9/20 0.51
▸ HDAC7 Q8WUI4 9/20 0.51
▸ HDAC2 Q92769 9/20 0.51
▸ HDAC10 Q969S8 9/20 0.51
▸ HDAC11 Q96DB2 9/20 0.51
▸ HDAC8 Q9BY41 9/20 0.51
▸ HDAC6 Q9UBN7 9/20 0.51
▸ HDAC9 Q9UKV0 9/20 0.51
▸ HDAC5 Q9UQL6 9/20 0.51
▸ BRD2 P25440 2/20 0.50
▸ CHEK2 O96017 1/20 0.50
▸ CSNK1A1 P48729 1/20 0.50
▸ CSNK1D P48730 1/20 0.50
▸ CSNK1E P49674 1/20 0.50
▸ CSNK1G2 P78368 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377968 0.93 BRD4 (0.57) BRD4ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL377623 0.91 BRD4 (0.58) BRD4ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL377628 0.91 ALDH1A1 (0.55) BRD4ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL377547 0.88 BRD4 (0.59) BRD4ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL377614 0.86 BRD4 (0.52) BRD4GAAHDAC3HDAC4HDAC1
SCHEMBL378261 0.86 BRD4 (0.52) BRD4ALDH1A1GAAHDAC3HDAC4
SCHEMBL378189 0.86 BRD4 (0.57) BRD4ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL377766 0.85 BRD4 (0.56) BRD4ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL31115553 0.85 BRD4 (0.56) BRD4ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL378514 0.85 BRD4 (0.56) BRD4ALDH1A1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 — — EP claimed
US-10131640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2018-11-20 — — US claimed
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2016-05-19 — — US claimed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US claimed
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 — — EP disclosed
US-11407719-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2022-08-09 — — US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 — — US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 — — US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 — — US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 — — US disclosed
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2019-04-25 — — US disclosed
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2019-04-25 — — US disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 — — US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 — — US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 — — US disclosed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 — — EP disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 — — WO disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407719-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 BRD4 744/4885ALDH1A1 587/4885GAA 3104/4885
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 700/4885ALDH1A1 650/4885GAA 3119/4885
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 BRD4 10/4885ALDH1A1 3920/4885GAA 1418/4885
US-10882828-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 BRD4 744/4885ALDH1A1 587/4885GAA 3104/4885
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 744/4885ALDH1A1 587/4885GAA 3104/4885
US-10131640-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 BRD4 744/4885ALDH1A1 587/4885GAA 3104/4885
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 700/4885ALDH1A1 650/4885GAA 3119/4885
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 700/4885ALDH1A1 650/4885GAA 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.